Intellia Therapeutics

Yahoo Finance • 25 days ago

This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?

Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics(NASDAQ: NTLA), fits the bill. Intellia is a mid-ca... Full story

Yahoo Finance • 29 days ago

Roblox initiated, Target upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Telsey Advisory upgraded Target (TGT)... Full story

Yahoo Finance • 30 days ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood seems to always be making market moves. The founder and CEO of Ark Invest publishes her transactions at the end of every trading day, and that gives us all a great way to track one of the most widely followed growth investors.... Full story

Yahoo Finance • last month

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory

We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $12.48 as of February 18th.... Full story

Yahoo Finance • last month

Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2

Earnings Call Insights: Intellia Therapeutics (NTLA) Q4 2025 MANAGEMENT VIEW * CEO John Leonard highlighted that "with up to 3 years of patient follow-up, we have yet to see any waning of effect in serum kallikrein or TTR levels in the... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while boosting its price target... Full story

Yahoo Finance • 2 months ago

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and gover... Full story

Yahoo Finance • 2 months ago

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could revolutionize medicine by helping researcher... Full story

Yahoo Finance • 2 months ago

Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Intellia Therapeutics, Inc. is positioned seventh on our list. TheFly reported on January 28 that Baird raised its price target on NTLA to $7 from $4 while ma... Full story

Yahoo Finance • 3 months ago

What Makes Intellia Therapeutics (NTLA) an Interesting Investment?

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% i... Full story

Yahoo Finance • 3 months ago

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

Key Points A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges. 10 stocks we like better than Intell... Full story

Yahoo Finance • 4 months ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on Decembe... Full story

Yahoo Finance • 4 months ago

Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the most oversold biotech stocks to invest in. On November 11, Jones Trading dropped Intellia Therapeutics, Inc. (NASDAQ:NTLA) from Buy to Hold. The downgrade came after Intellia announ... Full story

Yahoo Finance • 4 months ago

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdatesNews Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focu... Full story

Yahoo Finance • 4 months ago

Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Evercore ISI downgraded Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In Line and cut its price targ... Full story

Yahoo Finance • 5 months ago

Intellia cut to Peer Perform at Wolfe Research on Nex-z safety issues

[Wall Street New York stock exchange stock market] alexsl Intellia Therapeutics (NTLA [https://seekingalpha.com/symbol/NTLA]) downgraded to a Peer Perform rating from Outperform at Wolfe Reseach, primarily due to emerging safety concerns... Full story

Yahoo Finance • 5 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA... Full story

Yahoo Finance • 5 months ago

Cathie Wood's Ark Invest weekly moves: Adds to ACHR and CRSP, trims positions in ROKU and SOFI

[Wooden Blocks with ETF Letters Surrounded by Coins and Financial Icons Representing Investment Growth and Financial Strategies in a Modern Finance Context] Suphachai Panyacharoen Cathie Wood’s ARK Invest reshuffled its portfolio this wee... Full story

Yahoo Finance • 5 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (75%) were attack-free and LTP-free for... Full story

Yahoo Finance • 5 months ago

Intellia hit with multiple downgrades following pause in phase 3 nex-z program

[Wall street district in New York City with USA flags in the background] FilippoBacci At least five Wall Street firms have downgraded their ratings on Intellia Therapeutics (NASDAQ:NTLA [https://seekingalpha.com/symbol/NTLA]) in the wake... Full story